Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 9/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4940874 | 0.80 | PDGFRB (0.44) | MEN1ALDH1A1MAPTHPGDPTBP1 | |
| SCHEMBL8263981 | 0.74 | BACE1 (0.50) | MEN1ALDH1A1MAPTHPGDPTBP1 | |
| SCHEMBL8265305 | 0.73 | BACE1 (0.59) | MEN1ALDH1A1MAPTKMT2ABACE1 | |
| SCHEMBL14007505 | 0.72 | BACE1 (0.68) | ALDH1A1MAPTHPGDKMT2ABACE1 | |
| SCHEMBL8265285 | 0.70 | BACE1 (0.66) | ALDH1A1MAPTHPGDKMT2ABACE1 | |
| SCHEMBL8264459 | 0.70 | BACE1 (0.66) | MEN1ALDH1A1HPGDKMT2ABACE1 | |
| SCHEMBL8264443 | 0.69 | KMT2A (0.48) | MEN1ALDH1A1MAPTKMT2ABACE1 | |
| SCHEMBL8265306 | 0.69 | BACE1 (0.44) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4934632 | 0.68 | BACE1 (0.59) | MEN1ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL9746628 | 0.67 | BACE1 (0.62) | MEN1ALDH1A1MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | MEN1 3533/4885ALDH1A1 1429/4885MAPT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.